NYSE:LLY

Eli Lilly and Stock Forecast, Price & News

$145.16

-0.40 (-0.27 %)

(As of 12/2/2020 12:00 AM ET)

Add

Compare

Today's Range

$144.38

Now: $145.16▼

$147.09

50-Day Range

$130.46

MA: $142.18▼

$150.08

52-Week Range

$115.92

Now: $145.16▼

$170.75

Volume3.72 million shs

Average Volume3.96 million shs

Market Capitalization$138.86 billion

P/E Ratio23.72

Dividend Yield2.03%

Beta0.27

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Eli Lilly and has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $168.93, Eli Lilly and has a forecasted upside of 16.4% from its current price of $145.16.
Amount of Analyst Coverage
Eli Lilly and has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Eli Lilly and has received 1,018 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eli Lilly and has received 835 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eli Lilly and has received 54.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote “Outperform” if you believe LLY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Yield
Eli Lilly and pays a meaningful dividend of 2.03%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Eli Lilly and has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly and is 49.01%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 37.90% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly and insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $755,050.00 in company stock.
Percentage Held by Insiders
Only 0.09% of the stock of Eli Lilly and is held by insiders.
Percentage Held by Institutions
69.85% of the stock of Eli Lilly and is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly and are expected to grow by 9.69% in the coming year, from $7.12 to $7.81 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly and is 23.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 20.73.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly and is 23.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.52.
Price to Earnings Growth Ratio
Eli Lilly and has a PEG Ratio of 1.34. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly and has a P/B Ratio of 27.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.30 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:LLY

Previous Symbol

CUSIP53245710

CIK59478

Webwww.lilly.com

Phone317-276-2000

Employees33,625

Debt

Debt-to-Equity Ratio3.27

Current Ratio1.36

Quick Ratio1.06

Price-To-Earnings

Trailing P/E Ratio23.72

Forward P/E Ratio20.39

P/E Growth1.34

Sales & Book Value

Annual Sales$22.32 billion

Price / Sales6.22

Cash Flow$7.10 per share

Price / Cash Flow20.44

Book Value$5.22 per share

Price / Book27.81

Profitability

EPS (Most Recent Fiscal Year)$6.04

Net Income$8.32 billion

Net Margins24.01%

Return on Equity166.45%

Return on Assets15.18%

Miscellaneous

Outstanding Shares956,582,000

Market Cap$138.86 billion

Next Earnings Date2/4/2021 (Estimated)

OptionableOptionable

$145.16

-0.40 (-0.27 %)

(As of 12/2/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

How has Eli Lilly and's stock been impacted by Coronavirus (COVID-19)?

Eli Lilly and's stock was trading at $140.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LLY stock has increased by 3.7% and is now trading at $145.16.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Eli Lilly and?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eli Lilly and or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Eli Lilly and?

Wall Street analysts have given Eli Lilly and a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eli Lilly and wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Eli Lilly and.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) announced its earnings results on Sunday, November, 1st. The company reported $1.54 earnings per share for the quarter, missing the consensus estimate of $1.71 by $0.17. The firm earned $5.74 billion during the quarter, compared to analyst estimates of $5.87 billion. Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The firm's quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.48 earnings per share.
View Eli Lilly and's earnings history.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, October 19th. Stockholders of record on Friday, November 13th will be paid a dividend of $0.74 per share on Thursday, December 10th. This represents a $2.96 annualized dividend and a dividend yield of 2.04%. The ex-dividend date is Thursday, November 12th.
View Eli Lilly and's dividend history.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY20 earnings guidance on Tuesday, October, 27th. The company provided EPS guidance of $7.20-$7.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.29. The company issued revenue guidance of $23.7-$24.2 billion, compared to the consensus revenue estimate of $23.79 billion.

What price target have analysts set for LLY?

15 brokers have issued 1 year target prices for Eli Lilly and's stock. Their forecasts range from $144.00 to $200.00. On average, they anticipate Eli Lilly and's stock price to reach $168.93 in the next year. This suggests a possible upside of 16.4% from the stock's current price.
View analysts' price targets for Eli Lilly and.

Are investors shorting Eli Lilly and?

Eli Lilly and saw a increase in short interest in November. As of November 15th, there was short interest totaling 5,330,000 shares, an increase of 9.0% from the October 31st total of 4,890,000 shares. Based on an average daily trading volume, of 4,030,000 shares, the short-interest ratio is currently 1.3 days. Currently, 0.7% of the shares of the stock are sold short.
View Eli Lilly and's Short Interest.

Who are some of Eli Lilly and's key competitors?

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Endo International (ENDP).
View all competitors.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), The Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the following people:

Mr. David A. Ricks, Chairman, CEO & Pres (Age 52, Pay $4.4M)
Mr. Joshua L. Smiley, Sr. VP & CFO (Age 50, Pay $2.13M)
Dr. Daniel M. Skovronsky, Sr. VP, Chief Scientific Officer & Pres of Lilly Research Labs (Age 47, Pay $2.14M)
Mr. Jacob S. Van Naarden, Chief Operating Officer of Loxo Oncology (Age 35)
Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin.
Mr. Martin Bott MIBS, VP of Fin. & Special Projects (Age 57)
Ms. Aarti Shreyas Shah Ph.D., Sr. VP & Chief Information and Digital Officer (Age 55)
Kevin Hern, VP of Investor Relations
Ms. Melissa Stapleton Barnes, Sr. VP of Enterprise Risk Management and Chief Ethics & Compliance Officer (Age 52)
Ms. Anat Hakim J.D., Sr. VP & Gen. Counsel (Age 51)

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.62%), BlackRock Inc. (6.32%), State Street Corp (3.65%), Nuveen Asset Management LLC (0.82%), Fisher Asset Management LLC (0.49%) and Jennison Associates LLC (0.48%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, David A Ricks, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

Which institutional investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., State Street Corp, Lilly Endowment Inc., Massachusetts Financial Services Co. MA, Charles Schwab Investment Management Inc., Los Angeles Capital Management & Equity Research Inc., and Schafer Cullen Capital Management Inc. Company insiders that have sold Eli Lilly and company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Lilly Endowment Inc, Melissa S Barnes, Myles O'neill, and Stephen F Fry.
View insider buying and selling activity for Eli Lilly and.

Which institutional investors are buying Eli Lilly and stock?

LLY stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., First Trust Advisors LP, State of Tennessee Treasury Department, Acadian Asset Management LLC, Arrowstreet Capital Limited Partnership, Jupiter Asset Management Ltd., Sirios Capital Management L P, and DekaBank Deutsche Girozentrale. Company insiders that have bought Eli Lilly and stock in the last two years include Anne E White, David A Ricks, Jackson P Tai, and Joshua L Smiley.
View insider buying and selling activity for Eli Lilly and.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $145.16.

How big of a company is Eli Lilly and?

Eli Lilly and has a market capitalization of $138.86 billion and generates $22.32 billion in revenue each year. The company earns $8.32 billion in net income (profit) each year or $6.04 on an earnings per share basis. Eli Lilly and employs 33,625 workers across the globe.

What is Eli Lilly and's official website?

The official website for Eli Lilly and is www.lilly.com.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings